Low & middle income vs Singapore: Immunization, Hib3
Low & middle income
75.7%
in 2024
Singapore
97.0%
in 2024
Low & middle income rank
29th
Singapore rank
29th
Immunization, Hib3 over time
- Low & middle income
- Singapore
How they compare
Singapore currently reports 97.0% against 75.7% in Low & middle income, a difference of 21.3%.
That makes Singapore's figure about 1.3 times Low & middle income's.
Across all 12 years both countries report, Singapore has been ahead every year.
Low & middle income ranks 29th and Singapore ranks 29th of 43 groups.
Singapore has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Low & middle income | Singapore | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 62.6% | 93.1% | 30.6% | Singapore |
| 2020s | 72.8% | 97.6% | 24.8% | Singapore |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Low & middle income or Singapore?
- Singapore, at 97.0% against 75.7% in Low & middle income as of 2024.
- What is the difference in immunization, hib3 between Low & middle income and Singapore?
- 21.3%, with Singapore ahead.
- How many years of comparable data are there for Low & middle income and Singapore?
- 12 years are reported by both, from 2013 to 2024.
- How do Low & middle income and Singapore rank globally for immunization, hib3?
- Low & middle income ranks 29th and Singapore ranks 29th of 43 groups.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.